CollPlant Biotechnologies (CLGN) Expands Vergenix™ STR Distribution in Europe for Tendon Injuries

CollPlant Biotechnologies Expands Distribution of Vergenix™ STR in Europe

CollPlant Biotechnologies (NASDAQ: CLGN), a frontrunner in regenerative and aesthetic medicine, announces a pivotal expansion of its European distribution network for its innovative product, Vergenix™ STR. This new partnership in Poland aims to enhance the availability of Vergenix™ STR, a soft tissue repair matrix designed specifically for treating a variety of tendon injuries, including lateral epicondylitis, rotator cuff injuries, patellar tendinopathy, Achilles tendon injuries, and hand tendon repairs. By leveraging the company's proprietary rhCollagen technology, Vergenix™ STR offers a novel approach to tendon healing, setting a new standard in the treatment landscape.

The unique formulation of Vergenix™ STR combines cross-linked rhCollagen with platelet-rich plasma (PRP), creating a durable scaffold that maximizes retention at the injury site. This innovative blend enables the localized release of growth factors that are essential for promoting optimal healing. Yehiel Tal, CEO of CollPlant, emphasizes that this differentiation is crucial for addressing the significant unmet needs in tendon repair therapies. The strategic partnership in Poland not only facilitates immediate access to the product but also aligns with CollPlant's broader vision of expanding its global footprint in the regenerative medicine market.

With plans to deliver the first shipment to its new distributor by the end of 2025, CollPlant is poised to tap into substantial market potential in both Europe and the Asia-Pacific region. This expansion represents a critical step for the company as it strives to increase its influence in the regenerative medicine sector. By focusing on innovative solutions like Vergenix™ STR, CollPlant is committed to enhancing patient outcomes through advanced therapeutic options tailored for soft tissue injuries.

In addition to its partnership in Poland, CollPlant continues to explore further opportunities to broaden its distribution network globally. The company’s focus on regenerative medicine is timely, as the demand for effective treatments for tendon injuries continues to rise, driven by an aging population and increasing physical activity levels. As such, CollPlant stands at the forefront of a growing industry, ready to make significant contributions to the field of regenerative medicine.